Biosyent Inc
XTSX:RX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Biosyent Inc
XTSX:RX
|
155.4m CAD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Biosyent Inc
Glance View
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Biosyent Inc is 77.5%, which is below its 3-year median of 80.1%.
Over the last 3 years, Biosyent Inc’s Gross Margin has decreased from 81.2% to 77.5%. During this period, it reached a low of 77.5% on Sep 30, 2025 and a high of 82.6% on Mar 31, 2023.
